U.S. Semiconductors Stock News

Rivian recently used its first Autonomy & AI Day to unveil an in-house 5nm autonomy chip, a next-generation ACM3 compute module with LiDAR for upcoming R2 models, and an Autonomy+ subscription service, while also announcing a future hands-free driving feature for current R1 vehicles. At the same time, former Patagonia CEO Rose Marcario’s decision to leave Rivian’s board while remaining chair of the Rivian Foundation underscores how the company is coupling an advanced autonomy roadmap with an...

National Health Investors (NHI) has quietly rewarded patient shareholders, with the stock up about 17% over the past year while maintaining steady revenue and earnings growth. This makes it an interesting income-focused REIT to revisit. See our latest analysis for National Health Investors. That steady climb in sentiment is visible in the numbers, with the latest share price at $77.84, a positive year to date share price return, and a strong one year and multi year total shareholder return...

Gilead Sciences (GILD) just strung together a trio of catalysts that the market could not ignore, including fresh HIV wins and a high profile U.S. drug pricing deal that reframes its long term growth story. See our latest analysis for Gilead Sciences. The latest HIV data and U.S. pricing accord appear to be feeding into a stronger narrative for Gilead, with the stock’s share price up meaningfully year to date and longer term total shareholder returns reinforcing that momentum. If...

PACS Group, Inc. recently named Kelly Priegnitz as Chief Compliance Officer and Trent Bingham as Chief Human Resources Officer, bolstering its leadership in compliance and workforce management after a series of acquisitions and a credit agreement amendment earlier in 2025. The addition of seasoned executives with deep healthcare compliance and human capital experience underscores PACS Group’s focus on governance, culture, and operational discipline as it grows its skilled nursing...

If you are wondering whether Synopsys is still worth buying at these levels or if the best gains are already in the rearview mirror, this article will walk you through what the current price really implies. The stock has bounced about 2.4% over the last week and roughly 20.0% over the past month, even though it is still down around 3.9% year to date and about 5.8% over the last year. Longer term holders remain well ahead with 44.8% and 80.9% returns over 3 and 5 years. Behind those swings,...

In recent months, United Parcel Service has moved ahead with a broad overhaul of its business, cutting tens of thousands of jobs, consolidating facilities, investing in automation, and expanding into higher-margin areas like healthcare logistics while also rolling out AI tools to curb fraudulent retail returns. Early signs such as rising revenue per package, a long-running commitment to its dividend, and a pivot away from lower-margin e-commerce work suggest UPS is reshaping its core...

If you are wondering whether Norfolk Southern at around $291 a share is still worth climbing aboard or if the train has already left the station, this piece is for you. The stock is up 24.2% year to date and 27.1% over the last year, even after a recent 1.9% dip this week and a 3.4% gain over the past month. This hints that the market is still actively reassessing its long term prospects. Recent headlines have focused on Norfolk Southern’s ongoing safety and network efficiency initiatives,...

Earlier this month, Harmony Biosciences announced initial open-label extension data from its Phase 3 ARGUS trial of EPX-100 in Dravet syndrome, showing clinically meaningful seizure reductions and a generally favorable safety profile over long-term treatment. Beyond the seizure data, the twice-daily liquid EPX-100, derived from a proprietary zebrafish screening platform targeting 5HT-2 serotonin receptors, highlights Harmony’s push into rare, treatment-resistant epilepsies such as Dravet and...

If you are wondering whether EVERTEC at around $29 a share is a value opportunity or a value trap, you are not alone. That is exactly what we are going to unpack here. Despite a modest 0.6% gain over the last month, the stock is still down 15.8% year to date and 13.1% over the past year, which suggests sentiment has cooled even as the underlying business keeps grinding on. Recent headlines around digital payments infrastructure in Latin America and the Caribbean, along with ongoing shifts...

BigBear.ai Holdings (BBAI) is back on traders radar after unveiling a new partnership with C Speed that plugs its ConductorOS AI engine into C Speed radar systems for real time defense threat detection. See our latest analysis for BigBear.ai Holdings. That C Speed deal lands after a choppy stretch where dilution worries and the Ask Sage acquisition weighed on sentiment, yet BigBear.ai still sports a punchy year to date share price return and a triple digit one year total shareholder return...

Wondering if Netflix is still worth buying after its big run over the last few years, or if the easy money has already been made? You are not alone. That is exactly what this breakdown is here to unpack. Despite a powerful 220.0% gain over 3 years and 83.6% over 5 years, the stock has cooled recently, with a 6.4% year to date rise, 3.8% over the last year, but a softer -14.2% in the last month and -0.8% over the last week. This hints at shifting sentiment and a more nuanced risk reward...

Earlier this month, iRadimed Corporation’s board approved a special cash dividend of US$0.50 per share, payable on December 30, 2025, to shareholders of record as of December 17, 2025. This one-off payout highlights the company’s capacity to return excess cash to investors while its MRI-compatible devices continue to support recurring revenue streams. We’ll now examine how this special cash dividend, as a signal of balance-sheet strength, shapes IRADIMED’s existing investment...

DigitalOcean Holdings (DOCN) caught fresh attention after its shares climbed about 4% following the launch of its Gradient AI Agent Development Kit, which came on the heels of a multi year AI partnership with Persistent Systems. See our latest analysis for DigitalOcean Holdings. Beyond today’s pop, DigitalOcean’s 30 day share price return of 7.78% and 90 day share price return of 29.94% suggest momentum is building. A 3 year total shareholder return of 92% points to a compelling longer term...

If you are wondering whether UnitedHealth Group is now quietly trading at a discount after a rough stretch, or if that low price is a value trap in disguise, this breakdown is for you. After a choppy year, the stock is down about 35.1% year to date and 32.9% over the last 12 months, even though it has managed a 5.9% gain over the past month despite a 4.2% dip in the last week. Much of this volatility has been driven by headlines around rising medical cost trends, regulatory scrutiny in key...

TE Connectivity (TEL) has quietly delivered a strong run over the past year, and with shares hovering near 229 dollars, investors are starting to revisit whether the current price still reflects future growth potential. See our latest analysis for TE Connectivity. That steady climb in the share price to about 229.98 dollars, backed by a robust year to date share price return and a strong multi year total shareholder return, suggests momentum is still building as investors reassess TE...

In December 2025, Exxon Mobil updated its 2030 corporate plan, lifting expected earnings and cash flow by US$5.00 billion without raising capital spending, while also securing new North Sea offtake and financing agreements and facing operational changes such as the planned closure of its Fife Ethylene Plant in the UK. The company’s ability to project higher long-term profitability on the same capital budget, alongside disciplined shareholder returns and portfolio reshaping, highlights how...

If you are wondering whether Eli Lilly is still worth buying after its massive run up, or if the market has already priced in all the good news, you are not alone. The stock has climbed 4.3% over the last week, 37.7% year to date, and an enormous 577.5% over five years. This naturally raises questions about how much upside is really left from here. Recent gains have been driven largely by excitement around Eli Lilly's leadership in obesity and diabetes treatments, with blockbuster demand for...

Dominion Energy (D) has been getting fresh attention after its nuclear focused Memorandum of Understanding with Amazon and its inclusion among top utility picks for hedge funds, all against a backdrop of surging data center driven demand. See our latest analysis for Dominion Energy. Even with the Amazon nuclear partnership and hedge fund interest grabbing headlines, Dominion’s share price return has been steadier than explosive, with a roughly 9 percent year to date gain and a one year total...

If you are wondering whether Fluence Energy is still a smart buy after its recent run, or if the market has already priced in the upside, this article is for you. The stock has been volatile lately, dropping around 10% over the last week, but still up roughly 18.7% over the past month and 31.2% over the last year. This shows that sentiment can swing quickly. Recent attention has been driven by Fluence winning large scale energy storage contracts and expanding partnerships with major...

Wondering if Western Union at around $9.56 is a cheap cash cow or a value trap? Let us unpack whether the current price really reflects the underlying business. Over the last month the stock has climbed 13.1%, even though it is still down 8.4% year to date and 38.4% over 5 years, a mix that often signals shifting expectations rather than quiet stagnation. Recently, investors have been digesting Western Union's ongoing push into digital remittances and partnerships with fintech platforms, a...

Morgan Stanley just spotlighted Astera Labs (ALAB) as one of its top semiconductor picks for 2026, grouping it with Nvidia and Broadcom on the strength of AI and data center demand. See our latest analysis for Astera Labs. The endorsement appears to be resonating with investors, with Astera Labs' share price rising to $164.40 and delivering a 1 day share price return of 12.70 percent and a year to date share price return of 22.11 percent. The 1 year total shareholder return of 24.39 percent...

Home Depot (HD) is under a cloud of lowered earnings expectations right now, after a recent EPS miss and softer housing backdrop pushed analysts to trim forecasts and turn more cautious on the stock. See our latest analysis for Home Depot. Despite initiatives like faster delivery and the new Creator portal aimed at driving engagement, the share price has lost momentum recently. A 90 day share price return of negative 17.01 percent and a softer 1 year total shareholder return of negative 9.93...

Duke Energy recently announced a series of finance leadership changes, with longtime chief accounting officer Cindy Lee set to retire at the end of 2026 and investor relations head Abby Motsinger stepping into the senior vice president, chief accounting officer and controller role from March 1, 2026, alongside several internal promotions across treasury, risk and financial planning. By elevating investor relations and corporate development leaders into core finance roles as it executes a...

Morgan Stanley recently initiated coverage on Omnicom Group with an Equal Weight (hold) rating, while other research highlighted the company’s value credentials and earnings outlook, bringing renewed institutional attention to the advertising and marketing group. This mix of cautious analyst positioning and suggestions that Omnicom may be undervalued gives investors a fresh lens on how the market is currently assessing its earnings potential and risk profile. We’ll now examine how Morgan...